Generic Drugmaker Wins Review Of UCB's Vimpat Patent
The Patent Trial and Appeal Board on Monday accepted generic drugmaker Argentum Pharmaceuticals' petition to review a patent for UCB Inc.'s epilepsy drug Vimpat....To view the full article, register now.
Already a subscriber? Click here to view full article